Kiromic Biopharma, Inc.
Biotechnology Research
Houston, TX 5,843 followers
Cell therapy company with end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors
About us
Kiromic BioPharma is an allogeneic Gamma Delta T-cell therapy company featuring unique, proprietary, end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors. We are a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic’s DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn. OTCB: KRBP
- Website
-
http://www.kiromic.com
External link for Kiromic Biopharma, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Houston, TX
- Type
- Public Company
- Founded
- 2012
- Specialties
- Cancer Research, Tumor Immunology, Cell Culture, Biopharmaceutical, and Nanotechnology
Locations
-
Primary
Get directions
7707 Fannin Street
140
Houston, TX 77054, US
Employees at Kiromic Biopharma, Inc.
-
Lucia Piccotti, PhD, EMBA
Senior Director of Strategic Innovation
-
Michael Nagel
President & CEO Vomaris Innovations: Corporate Board Member, Commercializing Breakthrough Medical Technologies through: High-performing Teams |…
-
Leonardo Mirandola, PhD
CSO and Interim COO @ Kiromic Biopharma | Biotech Operations and Strategy
-
Brian Hungerford, CPA CGMA
Board Member, Executive, Consultant, Efficiency Expert, Automation Specialist, Entrepreneur, and Philanthropist
Updates
-
Please read about the promising results from the first cohort of three patients in our Deltacel-01 Phase 1 clinical trial at Beverly Hills Cancer Center. "Consistency in safety, tolerability, and disease stability is of paramount importance at this stage of testing, and the data thus far bolster our confidence in Deltacel's potential as a transformative treatment," stated Pietro Bersani, Chief Executive Officer of Kiromic BioPharma. “The findings are especially promising considering the robustness of response in the absence of brain metastasis, and the notable reduction in tumor size for the second and the first patient, respectively." #cartcelltherapy #celltherapy #patientsfirst https://lnkd.in/eVycTBzU
-
Continuing our mission to advance therapies for patients who have limited treatment options: our promising early clinical results continue as we report on our third patient from our Deltacel-01 Phase 1 clinical trial treating stage 4 metastatic non-small cell lung cancer (NSCLC) at Beverly Hills Cancer Center. #cartcelltherapy #celltherapy #patientsfirst https://lnkd.in/eEcfirVu
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial | Kiromic BioPharma, Inc.
ir.kiromic.com
-
Kiromic Biopharma, Inc. reposted this
Sharing how incredibly proud I am to be part of a team that can deliver these early results to late stage patients who have so few options - in our Deltacel-01 Phase 1 clinical trial treating stage 4 metastatic non-small cell lung cancer (NSCLC) Beverly Hills Cancer Center #cartcelltherapy #cart #gamechanging https://lnkd.in/eqi64Gkt
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial | Kiromic BioPharma, Inc.
ir.kiromic.com
-
Sharing how incredibly proud I am to be part of a team that can deliver these early results to late stage patients who have so few options - in our Deltacel-01 Phase 1 clinical trial treating stage 4 metastatic non-small cell lung cancer (NSCLC) Beverly Hills Cancer Center #cartcelltherapy #cart #gamechanging https://lnkd.in/eqi64Gkt
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial | Kiromic BioPharma, Inc.
ir.kiromic.com
-
Virginia Oncology Associates, PC is the second site activated in our ongoing Deltacel-01 Phase 1 clinical trial treating stage 4 metastatic non-small cell lung cancer (NSCLC) for patients who have limited treatment options. #cartcelltherapy #celltherapy #patientsfirst https://lnkd.in/ebxzBMRv
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial | Kiromic BioPharma, Inc.
ir.kiromic.com
-
Promising clinical results from our first patient show tumor reduction at two months! These are encouraging early findings from our Deltacel-01 Phase 1 clinical trial treating stage 4 metastatic non-small cell lung cancer (NSCLC) at Beverly Hills Cancer Center for patients who have limited treatment options. #cartcelltherapy #celltherapy #patientsfirst https://lnkd.in/eUCpnjQT
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months | Kiromic BioPharma, Inc.
ir.kiromic.com